Clinical Trial Update: A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase II study of low-dose recombinant human interleukin-2 for primary Sjögren's syndrome has completed enrollment. The trial status is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Low-dose recombinant human interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Primary Sjögren's Syndrome | Phase 2 | Status: COMPLETED